Pharmacovigilance
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| FEGONA (Fingolimod) |
FEGONA (Fingolimod): Risk related to the effects of FEGONA on the immune system. |
||
| Fingolimod (Gilenya®) |
Risks related to the effects on the immune system . |
||
| Xarelto ® (Rivaroxaban) |
Warnings and precautions for use to reduce the risk of bleeding. |
||
| Motilium® (Domperidone) |
New recommendations to minimise the cardiac risks . |
||
| Amistop® (Domperidone) |
New recommendations to minimise the cardiac risks . |
||
| Mododom® (Domperidone) |
New recommendations to minimise the cardiac risks . |
||
| Prokinin® (Domperidone) |
New recommendations to minimise the cardiac risks . |
||
| Arzerra® (ofatumumab) |
Safety update on a fatal infusion reaction reported in a patient with Chronic lymphocytic leukemia (CLL) who was treated with intravenous ofatumumab . |
||
| Arzerra® (ofatumumab) |
change to safety information regarding update to hepatitis B virus reactivation warning . |
||
| Riacavilol® (Carvedilol) |
Important safety update of prescribing information for Carvidol® (Carvedilol) |
